Michael Gorenstein, CEO, The Cronos Group, Canada
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through…
Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined…
Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration…
Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a…
Investissement Québec is a public corporation whose mission is to contribute to Québec’s economic development. Investissement Québec’s project manager, Stéphanie Murphy, discusses the role and contribution of pharmaceutical companies to…
MEDEC is the national association created by and for the Canadian medical technology industry. Brian Lewis, MEDEC’s CEO explains the challanges in advocating for a responsive, safe and sustainable healthcare system…
Charles River is the fifth largest CRO globally and the Canadian affiliate is the largest preclinical organization worldwide. Glenn Washer talks to us about the environment for contract research in…
Rémi Quirion, Chief Scientist of Québec, discusses how Canada needs to promote itself more aggressively, and highlights ways in which Canada can use industry-academia partnerships to its advantage, as well…
Wayne Samuels, partner at PwC Canada, discusses the most pressing issues in the country’s healthcare system and pharmaceutical industry, and outlines the changing dynamics in Canada’s pharma business model. What…
Michael Seckler of Ferring Canada offers his input about the affiliate’s recent restructuring, as well as the challenges of Canada’s reimbursement and pricing schemes and the advantages of the company’s…
Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D…
OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc.…
See our Cookie Privacy Policy Here
